Table 1.

Patients baseline characteristics.

Patients’ characteristics (n = 31)
Age at data collection, yr (range)	69 (22–89)
Age at diagnosis, yr	55
Female sex % (n)	65 (20)
Time on previous TKIs, months (range)	77 (13–221)
Disease stage before asciminib % (n)
Chronic phase	96 (30)
Accelerated phase	3 (1)
Blast phase	0
Sokal risk % (n)
Low	32 (10)
Intermediate	36 (11)
High	33 (10)
TKI at diagnosis % (n)
Imatinib	74 (23)
Dasatinib	10 (3)
Nilotinib	13 (4)
Bosutinib	3 (1)
Ponatinib	0 (0)
≥3 prior TKI lines % (n)	90 (28)
Prior use of ponatinib % (n)	35 (11)
BCR-ABL1 mutations % (n)	38 (12)
E255K % (n)	25 (3)
Exon 7 % (n)	17 (2)
T315I % (n)	8 (1)
Others % (n)	50 (6)